NY-LIME-TRADNG/TKEPROFIT
2.5.2024 14:01:30 CEST | Business Wire | Press release
Lime Trading Corp (“Lime Trading”), a tech-first agency broker headquartered in New York City, proudly announces its strategic partnership with west coast start up TakeProfit, a pioneering community-driven trader platform based in San Francisco, California. This collaboration was born from a joint belief that traders should have access to the best tools and technology no matter their strategy. This new partnership offers retail traders access to the newest innovations in charting and technical analysis, coupled with Lime Trading's industry-leading trade execution.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502144682/en/
The newly launched TakeProfit trading platform now offers widgets that integrate seamlessly with Lime Trading. Lime clients will be able to now place trades from the TakeProfit platform and view their portfolio all in one place. (Graphic: Business Wire)
Lime Trading is the only broker connected to TakeProfit, offering exclusive access to a trading widget native to the TakeProfit platform. Now traders can ideate and trade in one, seamless experience without ever leaving the platform. “We are thrilled to introduce this integration with TakeProfit,” remarked Johan Sandblom, CEO at Lime Trading. “By merging Lime Trading's expertise in trade execution with TakeProfit's innovative platform, we are equipping retail traders with the essential tools needed to help navigate today's dynamic markets efficiently.”
Alexey Shulzhenko, TakeProfit’s Founder & CEO said, “We partnered with Lime because they have a passion to build the best for traders, by traders. Their focus on providing all traders with lower latency technology aligns with our mission to bring traders the tools they need to trade more effectively.”
This partnership is just one of a few, recent product enhancements that Lime Trading has released to enhance their retail offering. Most recently they’ve added a Python SDK for their REST API and streamlined their demo paper trading access for traders to test drive Lime for themselves.
Traders wanting to try the TakeProfit trade integration that do not yet have a Lime account to experience this new integration, are able to sign up for a free demo paper account. For more information regarding Lime Trading and TakeProfit's new partnership, visit m.lime.co/takeprofit.
About Lime Trading
For over twenty years, Lime Trading has been focused on developing tools and technology to enhance traders’ access to markets. Focused on lower latency execution, Lime Trading works with retail and institutional clients alike to offer a broad range of APIs, platforms, and technology solutions to traders worldwide. Lime Trading Corp is an SEC-registered broker-dealer, member of FINRA/SIPC/NFA. For more information, visit Lime.co.
About TakeProfit
TakeProfit is a community-driven trading platform equipped with monetization tools for traders. It facilitates sharing research and making better trading decisions, allowing members to capitalize on their expertise. Workspaces are created using widgets, providing a customizable trading environment with immersive charting, custom indicators, screeners, financials, and other tools. TakeProfit brings desktop functionality to the web, utilizing new browser technologies and leveraging the advantages of cloud products. Learn more about TakeProfit at TakeProfit.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502144682/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces Clinical Milestone with First Patient Dosed in Phase 1 Trial of IDEAYA’s First-in-Class B7H3/PTK7 Bispecific TOP1 ADC IDE03428.2.2026 01:00:00 CET | Press release
IDE034 is a B7H3/PTK7 bispecific TOP1 ADC designed to target tumor cells expressing both B7H3 and PTK7 preferentially, and is being evaluated as monotherapy and in combination with IDEAYA’s PARG inhibitor IDE161. IDEAYA has dosed the first patient in its Phase 1 trial of IDE034, initially evaluating safety, tolerability, and PK. First dosing triggers a $5 million milestone payment to Biocytogen under the companies’ option and license agreement. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner IDEAYA Biosciences, Inc. (“IDEAYA”; Nasdaq: IDYA) has dosed the first patient in IDEAYA’s Phase 1 dose-escalation/expansion clinical trial of IDE034, an investigational B7H3/PTK7 bispecific TOP1 ADC. Pursuant to the companies’ option and license agreement, first patient dosing triggers a $5 million
IQM and Real Asset Acquisition Corp. to Host Conference Call/Webcast to Discuss Proposed Transaction27.2.2026 13:00:00 CET | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”), and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), announced that they will host a conference call to discuss their recently announced business combination, including certain transaction highlights. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260227472716/en/ IQM Radiance quantum computer As previously disclosed, on February 23, 2026, IQM and RAAQ announced they have entered into a definitive business combination agreement, which will result in IQM becoming a public company and listing American Depositary Shares on one of the two leading U.S. stock exchanges. The transaction provides funding with the aim to accelerate IQM’s technology and commercial development towards fault-tolerance quantum computing, further advancing its position as a leading p
HighRadius Launches $0 Implementation Fee, $0 Subscription Fee via Outcome Based Pricing for oCFO Software27.2.2026 12:00:00 CET | Press release
HighRadius launches Office of the CFO first Outcome Based Pricing with $0 Implementation fee and $0 Subscription until Go-Live. Customers only pay a fraction of realized gains based on P&L impact. Chapter 1: Outcome Based Pricing (OBP)Introduction of OBP: HighRadius, a provider of 190+ AI agents for Order-to-Cash, Accounts Payable, Record-to-Report, and Treasury introduces Outcome Based Pricing (OBP). Three Components of OBP: Customers pay a) $0 in Implementation fees, b) $0 in Subscription fees until Go Live, c) HighRadius earns a fraction of the actual savings realized by the client. Chapter 2: US GAAP & ASC 606 ConstraintsNot Designed for Innovation: The traditional ASC 606 model requires companies to standardize and recognize revenue based on contractual obligations. For a traditional SaaS subscription, the obligation is access to software over time. AI agents are designed to deliver quantifiable, real-time Business Outcomes that do not fit the traditional accounting framework. Cha
Kioxia Appoints Yoshihiko Kawamura as Chief Financial Officer27.2.2026 09:15:00 CET | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced the appointment of Yoshihiko Kawamura as Chief Financial Officer (CFO), effective April 1, 2026. Mr. Kawamura brings extensive international experience to Kioxia, having held assignments at Mitsubishi Corporation’s U.S. headquarters, served as General Manager of its Chicago office, and completed a tenure at the World Bank. At Hitachi, Ltd., he held senior leadership positions, including Chief Strategy Officer (CSO), Chief Financial Officer (CFO), and Chief Risk Management Officer (CRMO), where he was instrumental in leading the company’s management reforms. Since joining Kioxia as Executive Vice President in June 2025, Mr. Kawamura has worked closely with the executive team to advance the business through strategic capital and financial planning. Following its initial public offering on the Prime Market of the Tokyo Stock Exchange in December 2024, Kioxia is entering a new phase of growth char
DNP Invests in Rapidus to Support the Establishment of Mass Production for Next-Generation Semiconductors27.2.2026 08:18:00 CET | Press release
Will accelerate the development and mass production of EUV lithography photomasks Dai Nippon Printing Co., Ltd. (DNP, TOKYO:7912) today announced that it has participated in Rapidus Corporation’s funding round as one of the round investors. This strategic funding initiative supports Rapidus’ plan to steadily progress from its current R&D phase to mass production of 2nm (10⁻⁹ meters) logic semiconductors by 2027. Through this initiative, DNP will advance the development and mass production of EUV lithography photomasks and support Rapidus as it establishes a mass production system for 2nm & next-generation semiconductors. Background In recent years, the rise in energy consumption, in line with increased data generation, has become a challenge, driving demand for next-generation semiconductors capable of improving device performance and reducing power consumption. Next-generation semiconductors manufactured using EUV lithography enable the formation of finer patterns on silicon wafers co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom